CVS Health Corporation $CVS Shares Sold by Townsquare Capital LLC

Townsquare Capital LLC lessened its holdings in shares of CVS Health Corporation (NYSE:CVS) by 41.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,844 shares of the pharmacy operator’s stock after selling 11,852 shares during the period. Townsquare Capital LLC’s holdings in CVS Health were worth $1,337,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd raised its position in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares in the last quarter. Ares Financial Consulting LLC acquired a new stake in shares of CVS Health in the 4th quarter valued at about $29,000. Dogwood Wealth Management LLC boosted its position in shares of CVS Health by 93.7% in the 4th quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock valued at $29,000 after purchasing an additional 179 shares during the period. GoalVest Advisory LLC acquired a new stake in shares of CVS Health in the 4th quarter valued at about $32,000. Finally, MidAtlantic Capital Management Inc. acquired a new stake in shares of CVS Health in the 4th quarter valued at about $35,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Up 1.1%

CVS Health stock opened at $98.10 on Thursday. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $98.61. The stock has a 50 day moving average of $85.75 and a two-hundred day moving average of $80.47. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $125.16 billion, a price-to-earnings ratio of 43.21, a PEG ratio of 0.95 and a beta of 0.62.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same period last year, the firm earned $2.25 EPS. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark expanded coverage options for GLP-1 weight management medications, which could improve access for members and support pharmacy benefit growth while reinforcing CVS’s role in a high-demand therapeutic category. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications With Expanded Coverage Options
• Positive Sentiment: Investor sentiment also improved after commentary that CVS is in a meaningful turnaround, with recent results showing stronger insurance performance and improving retail pharmacy market share. CVS Offers A Compelling Turnaround Opportunity Not Seen In Years
• Positive Sentiment: CVS was recognized for technology that improves medication safety and patient care, supporting the company’s long-term narrative around innovation and healthcare delivery efficiency. CVS Health Recognized for Technology That Improves Medication Safety and Patient Care
• Neutral Sentiment: CVS named Zach Dennett as interim merchandising leader after Musab Balbale departed the company, a leadership change that may draw attention but is not clearly material on its own. Musab Balbale Departs CVS Health; Zach Dennett Named Interim Merchandising Leader
• Neutral Sentiment: CVS also announced an AI Learning Academy for employees, underscoring ongoing investments in automation and workforce training, though the near-term stock impact is likely limited. CVS launched an AI Learning Academy for its workforce. Here’s why
• Negative Sentiment: Reports that major hospitals are suing CVS over an alleged drug discount scheme could raise legal and reputational risks, which may pressure the stock if the case gains traction. Major hospitals sue CVS over alleged drug discount scheme

Wall Street Analyst Weigh In

A number of analysts recently issued reports on CVS shares. Piper Sandler reissued an “overweight” rating and issued a $113.00 target price on shares of CVS Health in a research report on Monday, June 1st. Morgan Stanley upped their target price on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. Wells Fargo & Company upped their target price on CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. TD Cowen upped their target price on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Finally, Sanford C. Bernstein increased their target price on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 12th. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $100.68.

Insider Activity

In related news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,441,551 shares of company stock valued at $323,703,977 over the last three months. 0.85% of the stock is currently owned by corporate insiders.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.